Serum protein profiling in mice: Identification of Factor XIIIa as a potential biomarker for muscular dystrophy

Proteomics

Volumn 8, Issue 8, 2008, Pages 1552-1563

  Alagaratnam, Sharmini ^a   Mertens, Bart J A ^a   Dalebout, Johannes C ^a   Deelder, André M ^a   Van Ommen, Gert Jan B ^a   Den Dunnen, Johan T ^a   'T Hoen, Peter A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Duchenne muscular dystrophy; Factor XIIIa; MALDI MS; Serum protein profiling

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13A; DYSTROPHIN;

ARTICLE; BAYES THEOREM; DNA DETERMINATION; FRACTIONATION; LOGISTIC REGRESSION ANALYSIS; MASS SPECTROMETER; MATHEMATICAL ANALYSIS; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RNA ANALYSIS; TECHNIQUE;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; DYSTROPHIN; FACTOR XIIIA; MICE; MICE, KNOCKOUT; MUSCULAR DYSTROPHY, DUCHENNE; PEPTIDE MAPPING; PROTEIN ARRAY ANALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

MUS;

EID: 42549137898     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700857     Document Type: Article

References (34)

1. Deburgrave, N., Daoud, F., Llense, S., Barbot, J. C. et al., Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum. Mutat. 2007, 28, 183-195.
2. White, S., Kalf, M., Liu, Q., Villerius, M. et al., Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am. J. Hum. Genet. 2002, 71, 365-374.
3. Coombes, K. R., Morris, J. S., Hu, J., Edmonson, S. R. et al., Serum proteomics profiling-a young technology begins to mature. Nat. Biotechnol. 2005, 23, 291-292.
4. Villanueva, J., Philip, J., Chaparro, C. A., Li, Y. et al., Correcting common errors in identifying cancer-specific serum peptide signatures. J. Proteome Res. 2005, 4, 1060-1072.
5. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116, 271-284.
6. Villanueva, J., Martorella, A. J., Lawlor, K., Philip, J. et al., Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 2006, 5, 1840-1852.
7. Morandi, L., Angelini, C., Prelle, A., Pini, A. et al., High plasma creatine kinase: Review of the literature and proposal for a diagnostic algorithm. Neurol. Sci. 2006, 27, 303-311.
8. Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A. et al., The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 1989, 244, 1578-1580.
9. Cox, G. A., Phelps, S. F., Chapman, V. M., Chamberlain, J. S., New >mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat. Genet. 1993, 4, 87-93.
10. Porter, J. D., Rafael, J. A., Ragusa, R. J., Brueckner, J. K. et al., The sparing of extraocular muscle in dystrophinopathy is lost in mice lacking utrophin and dystrophin. J. Cell Sci. 1998, 111, 1801-1811.
11. 't Hoen, P. A., de Meijer, E. J., Boer, J. M., Vossen, R. H. et al., Generation and characterization of transgenic mice with the full-length human DMD gene. J. Biol. Chem. 2008, 283, 5899-5907.
12. Turk, R., Sterrenburg, E., de Meijer, E. J., van Ommen, G. J. et al., Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics 2005, 6, 98.
13. Turk, R., Sterrenburg, E., van der Wees, C. G., de Meijer, E. J. et al., Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 2006, 20, 127-129.
14. Mertens, B. J. A., de Noo, M. E., Tollenaar, R. A., Deelder, A. M., Mass spectrometry proteomic diagnosis: Enacting the double cross-validatory paradigm. J. Comput. Biol. 2006, 13, 1591-1605.
15. le Cessie, S., van Houwelingen, J. C., Ridge estimators in logistic regression. Appl. Stat. J. Roy. St. C. 1992, 41, 191-201.
16. Mertens, B. J. A., in: Bernardo, J. M., Bayarri, M. J., Berger, J. O., Dawid, A. P. (Eds.), Bayesian Statistics 8, Oxford University Press, Oxford 2007, pp. 639-644.
17. de Noo, M. E., Mertens, B. J. A., Ozalp, A., Bladergroen, M. R. et al., Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 2006, 42, 1068-1076.
18. Hastie, T., Tibshirani, R., Friedman, J., in: Model Assessment and Selection, Springer, New York 2007, pp. 193-222.
19. Green, P. J., Reversible jump Markov chain Monte Carlo computation and Bayesian model determination. Biometrika 1995, 82, 711-732.
20. Richardson, S., Green, P. J., On Bayesian analysis of mixtures with an unknown number of components. J. Roy. Stat. Soc. Ser. B 1997, 59, 731-758.
21. Holmes, C. C., Held, L., Bayesian auxiliary variable models for binary and multinomial regression. Bayesian Anal. 2006, 1, 145-168.
22. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
23. Muto, Y., Satoh, J., Muto, G., Masuda, T. et al., Effect of long-term treatment with complete Freund's adjuvant on KK-Ay mouse, a model of non-insulin-dependent diabetes mellitus. Clin. Immunol. Immunop. 1997, 83, 53-59.
24. Mertens, B. J. A., Microarrays, pattern recognition and exploratory data analysis. Sfaf. Med. 2003, 22, 1879-1899.
25. Verweij, P. J. M., van Houwelingen, H. C., Penalized likelihood in Cox regression. Stat. Med. 1994, 13, 2427-2436.
26. Sane, D. C., Kontos, J. L., Greenberg, C. S., Roles of transglutaminases in cardiac and vascular diseases. Front. Biosci. 2007, 12, 2530-2545.
27. Torocsik, D., Bardos, H., Nagy, L., Adany, R., Identification of factor XIII-A as a marker of alternative macrophage activation. Cell. Mol. Life Sci. 2005, 62, 2132-2139.
28. Bakker, E. N. T. P., Pistea, A., Spaan, J. A. E., Rolf, T. et al., Flow-dependent remodeling of small arteries in mice deficient for tissue-type transglutaminase: Possible compensation by macrophage-derived Factor XIII. Circ. Res. 2006, 99, 86-92.
29. Porter, J. D., Guo, W., Merriam, A. P., Khanna, S. et al., Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscular Disord. 2003, 13, 223-235.
30. Tammen, H., Möhring, T., Kellmann, M., Pich, A., et al., Mass spectrometric phenotyping of blood coagulation factor XIII by differential peptide display. Clin. Chem. 2004, 50, 545-551.
31. Duan, D., Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum. Mol. Genet. 2006, 15, R253-R261.
32. Sterrenburg, E., Turk, R., 't Hoen, P. A. C., van Deutekom, J. C. T. et al., Large-scale gene expression analysis of human skeletal myoblast differentiation. Neuromuscular Disord. 2004, 14, 507-518.
33. Chen, Y. W., Zhao, P., Borup, R., Hoffman, E. P., Expression profiling in the muscular dystrophies: Identification of novel aspects of molecular pathophysiology. J. Cell Biol. 2000, 151, 1321-1336.
34. Schroeder, V., Vuissoz, J.M., Caflisch, A., Kohler, H.P., Factor XIII activation peptide is released into plasma upon cleavage by thrombin and shows a different structure compared to its bound form. Thromb. Haemost. 2007, 97, 890-898.